

Sponsored By:



## **Epilepsy Management System for the Treatment of Medically Intractable Epilepsy**

NeuroVista Corporation  
John Harris, CEO

NeuroVista Corporation is developing an Epilepsy Management System designed to address three of the major challenges in managing and treating medically refractory epilepsy. The system is capable of collecting a continuous, long-term, ambulatory record of the patient's EEG, enabling for the first time accurate quantification of clinical and subclinical seizure activity over time. This data may enable more informed pharmacotherapy to improve seizure control with fewer drug side effects. The platform's caregiver alert feature provides notification to a caregiver when seizures occur, enabling timely intervention and providing greater independence and quality of life for both patient and caregiver. Finally, the Epilepsy Management System's Seizure Advisory feature informs a patient of their likelihood of experiencing a seizure, enabling them to protect themselves from physical harm when seizures are highly likely, and engage with greater confidence in their daily activities when seizures are highly unlikely.

The Epilepsy Management System includes an Implantable Lead Assembly (ILA) which is implanted subdurally and provides the iEEG interface to the patient's cerebral cortex. The iEEG signals are received by an implantable telemetry unit (ITU) implanted in a sub-clavicular pocket. The ITU transmits the data wirelessly out of the patient's body to a Personal Advisory Device (PAD). The PAD is a pager-like device carried externally by the patient that receives continuous iEEG data from the ITU and processes the data in real time with a seizure advisory algorithm trained for the patient. The PAD provides continuous communication of seizure likelihood to the patient through a series of three advisory indicators corresponding to low, moderate, or high likelihood of seizure. The PAD also stores iEEG and advisory data on data cards for subsequent retrieval and analysis.

NeuroVista is presently engaged in a multi-center clinical study in Australia to assess the safety and effectiveness of the system. The Company initiated a 10 subject study in June of 2010 and has recently received approval to expand the study to 15 subjects. The safety profile of the first 10 subjects is very encouraging. The quality of the iEEG data and reliability of the device has been excellent and for most subjects, it has been possible to identify periods of increased seizure susceptibility.

The NeuroVista Epilepsy Management System is a disruptive technology with the potential to change the management and treatment of epilepsy. The platform is designed to enable people living with epilepsy to anticipate when seizures are likely to occur, alert caregivers when seizures do occur, and provide a continuous EEG record that will enable a more informed use of pharmacology for improved seizure control.

NeuroVista has pursued strong patent protection of its technology and has obtained 20 issued patents and 51 pending patent applications in the U.S. and abroad addressing various aspects of its technology.

The key development challenges for the Company are to complete the Australia multicenter study to assess the safety and effectiveness of the Epilepsy Management System and move toward full commercialization.

The Company's next key milestone is to complete enrollment of a 15 subject multi-center feasibility clinical study in Q2 2011.

The Company is seeking additional funds through investment or partnership to expand its clinical program and move toward commercialization.